share_log

Tempus AI | 10-Q: Q3 2024 Earnings Report

Tempus AI | 10-Q: Q3 2024 Earnings Report

Tempus AI | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/05 05:10

Moomoo AI 已提取核心信息

Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI公司公布了2024年第三季度强劲的财务业绩，总营业收入同比增长33%，达到18090万美元。基因组学营业收入增长20%，达到11640万美元，而数据和服务营业收入激增64%，达到6450万美元。该公司在该季度进行了大约69,000例肿瘤NGS测试，较2023年第三季度的55,700例有所增加。公司继续大力投资于研发，费用增加至5800万美元，而2023年第三季度为4740万美元。营业费用从去年的18080万美元上升至23450万美元，主要由于2100万美元的基于股票的补偿和增加的人事成本。净亏损从2023年第三季度的5340万美元扩大至7580万美元。Tempus通过宣布以现...展开全部
Tempus AI公司公布了2024年第三季度强劲的财务业绩，总营业收入同比增长33%，达到18090万美元。基因组学营业收入增长20%，达到11640万美元，而数据和服务营业收入激增64%，达到6450万美元。该公司在该季度进行了大约69,000例肿瘤NGS测试，较2023年第三季度的55,700例有所增加。公司继续大力投资于研发，费用增加至5800万美元，而2023年第三季度为4740万美元。营业费用从去年的18080万美元上升至23450万美元，主要由于2100万美元的基于股票的补偿和增加的人事成本。净亏损从2023年第三季度的5340万美元扩大至7580万美元。Tempus通过宣布以现金37500万美元和480万股A类普通股收购Ambry Genetics，进一步增强了其战略地位。该公司还通过与软银在日本的合资企业扩大了国际业务，为Sb Tempus贡献了9520万美元。截止到2024年9月30日，公司保持了强劲的资产负债表，现金及现金等价物为38890万美元。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点